Loading...
Worldwide, most deaths from malaria occur in infants and young children. One hurdle in treating pediatric patients is delivering antimalarial drugs in a form that achieves therapeutic blood levels. Artemisinin-containing combination therapy is now recommended for most areas and is being used in many countries.
In a single-blind study partly supported by industry, investigators compared the efficacy and safety of artemether-lumefantrine in two forms: newly developed dispersible cherry-flavored tablets and crushed conventional tablets. The study was conducted in five malaria-endemic African countries. Infants and children aged ≤12 years with acute uncomplicated falciparum malaria were admitted to a hospital and randomized to receive convention…